2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (Q34500921)

2 August 2017

title

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. (English)

1 reference

2 August 2017

1 reference

4

Elie A Akl

1 reference

2 August 2017

Raveendhara R Bannuru

object named as

Raveendhara R Bannuru

5

0 references

Jasvinder Singh

object named as

Jasvinder A Singh

1

0 references

Jeffrey R Curtis

11

object named as

Jeffrey R Curtis

1 reference

2 August 2017

23

E William St Clair

1 reference

2 August 2017

2

Kenneth G Saag

1 reference

2 August 2017

14

Arthur Kavanaugh

1 reference

2 August 2017

S Louis Bridges

3

1 reference

2 August 2017

Matthew C Sullivan

6

1 reference

2 August 2017

Elizaveta Vaysbrot

7

1 reference

2 August 2017

Christine McNaughton

8

1 reference

2 August 2017

Mikala Osani

9

1 reference

2 August 2017

Robert H Shmerling

10

1 reference

2 August 2017

Daniel E Furst

12

1 reference

2 August 2017

Deborah Parks

13

1 reference

2 August 2017

James O'Dell

15

1 reference

2 August 2017

Charles King

16

1 reference

2 August 2017

Amye Leong

17

1 reference

2 August 2017

Eric L Matteson

18

1 reference

2 August 2017

John T Schousboe

19

1 reference

2 August 2017

Barbara Drevlow

20

1 reference

2 August 2017

Seth Ginsberg

21

1 reference

2 August 2017

James Grober

22

1 reference

2 August 2017

Elizabeth Tindall

24

1 reference

2 August 2017

Amy S Miller

25

1 reference

2 August 2017

Timothy McAlindon

26

1 reference

2 August 2017

publication date

6 November 2015

1 reference

2 August 2017

published in

Arthritis & Rheumatology

1 reference

2 August 2017

volume

68

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

1-26

1 reference

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

2 August 2017

cites work

1 reference

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

21 January 2018

1 reference

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

21 January 2018

1 reference

GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength.

21 January 2018

1 reference

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions

21 January 2018

1 reference

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

21 January 2018

1 reference

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

21 January 2018

1 reference

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

21 January 2018

1 reference

Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study

21 January 2018

1 reference

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

21 January 2018

1 reference

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

21 January 2018

1 reference

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

21 January 2018

1 reference

Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies

21 January 2018

1 reference

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

21 January 2018

1 reference

Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial

21 January 2018

1 reference

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study.

21 January 2018

1 reference

Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis

21 January 2018

1 reference

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

21 January 2018

1 reference

Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial

21 January 2018

1 reference

Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis

21 January 2018

1 reference

Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolon

21 January 2018

1 reference

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

21 January 2018

1 reference

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis

21 January 2018

1 reference

Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial

21 January 2018

1 reference

The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis

21 January 2018

1 reference

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients

21 January 2018

1 reference

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

21 January 2018

1 reference

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

Therapies for active rheumatoid arthritis after methotrexate failure

21 January 2018

1 reference

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

21 January 2018

1 reference

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

21 January 2018

1 reference

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study

21 January 2018

1 reference

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

21 January 2018

1 reference

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor

21 January 2018

1 reference

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis

21 January 2018

1 reference

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study

21 January 2018

1 reference

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

21 January 2018

1 reference

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)

21 January 2018

1 reference

A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.

21 January 2018

1 reference

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

21 January 2018

1 reference

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy

21 January 2018

1 reference

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

21 January 2018

1 reference

Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

21 January 2018

1 reference

Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review

21 January 2018

1 reference

The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease

21 January 2018

1 reference

Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

21 January 2018

1 reference

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients

21 January 2018

1 reference

Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial

21 January 2018

1 reference

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

21 January 2018

1 reference

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

21 January 2018

1 reference

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.

21 January 2018

1 reference

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

21 January 2018

1 reference

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy

21 January 2018

1 reference

Rituximab (RTX) as an Alternative to TNF-Alpha Antagonists in Patients with Rheumatoid Arthritis and High Risk of Severe Infections: A Systematic Analysis of the Experience in One Center

21 January 2018

1 reference

Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.

21 January 2018

1 reference

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

21 January 2018

1 reference

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases

21 January 2018

1 reference

Management of patients with hepatitis B who require immunosuppressive therapy

21 January 2018

1 reference

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases

21 January 2018

1 reference

The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

21 January 2018

1 reference

Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate

21 January 2018

1 reference

Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

21 January 2018

1 reference

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

21 January 2018

1 reference

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

21 January 2018

1 reference

Sustained remission with etanercept tapering in early rheumatoid arthritis

21 January 2018

1 reference

The definition and measurement of disease modification in inflammatory rheumatic diseases

21 January 2018

1 reference

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states

21 January 2018

1 reference

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

21 January 2018

1 reference

The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List.

21 January 2018

1 reference

Going from evidence to recommendations

21 January 2018

1 reference

A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or compute

21 January 2018

1 reference

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

21 January 2018

1 reference

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

21 January 2018

1 reference

Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment

21 January 2018

1 reference

Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis

21 January 2018

1 reference

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.39480

1 reference

2 August 2017

1 reference